RET and adenocarcinoma: Another study by Yoon et al. [75] investigated the potential of the combined radiomic features, the PET parameters, the visual qualitative CT features, and the clinical data to differentiate the ALK/ROS1/RET fusion-positive and fusion-negative adenocarcinomas, building a model that resulted in 73% sensitivity and 70% specificity in the 10-fold cross validation (Table 11).